Table 1 Immunohistochemical analysis of USP22 expression with clinicopathology of CCA.

From: Operative ubiquitin-specific protease 22 deubiquitination confers a more invasive phenotype to cholangiocarcinoma

Tumour characteristics

USP22 protein expression

Total

p

Low

High

 Age (year)

  ≤50

7 (47%)

8 (53%)

15

0.389

  >50

25 (60%)

17 (40%)

42

 

 Sex

  Male

27 (55%)

22 (45%)

49

0.696

  Female

5 (63%)

3 (37%)

3

 

 γ-GT (U/L)

  ≤54

19 (56%)

15 (44%)

34

0.962

  >54

13 (57%)

10 (43%)

23

 

 Liver cirrhosis

  No

2 (67%)

1 (33%)

3

0.706

  Yes

30 (56%)

24 (44%)

54

 

 Tumor diameter

  ≤5

26 (67%)

13 (33%)

39

0.018

  >5

6 (33%)

12 (67%)

18

 

 Microvascular invasion

  Absent

22 (73%)

8 (27%)

30

0.006

  Present

10 (37%)

17 (63%)

27

 

 Tumor encapsulation

  Complete

14 (67%)

7 (37%)

21

0.221

  None

18 (50%)

18 (50%)

36

 

 Tumor differentiation

  I + II

26 (68%)

12 (32%)

38

0.080

  III + IV

6 (32%)

13 (68%)

19

 

 Lymph node metastasis

  No

20 (77%)

6 (23%)

26

0.004

  Yes

12 (39%)

19 (61%)

31

 

 TNM stage

  I

17 (57%)

13 (43%)

30

0.933

  II + III

15 (56%)

12 (44%)

27

 
  1. Correlation of USP22 protein expression with clinicopathology in 57 CCA in 2nd Hospital of Dalian Medical University, China.
  2. γ-GT γ-glutamyl transferase, TNM tumour-nodes metastasis.
  3. p-value was calculated using the Pearson χ2 test, and p < 0.05 was considered a statistically significant difference.
Back to article page